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ated with dose intensity of radiosensitizing Doc, and was diminished 
by dose reduction. Results suggest that this regimen should be further 
evaluated for stage III NSCLC. The PK disposition of Doc was similar 
at full-dose (75 mg/m2) and at low-dose (10 mg/m2 or 12 mg/m2) for 
Doc plasma clearance and half-life. Doc PK was not affected by the 
presence of cisplatin during induction CT. 
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Lung cancer in women: results of treatment
Cicenas, Saulius; Valuckas, Konstantinas P.; Aleknavicius, Eduardas; 
Aleknaviciene, Birute; Pipiriene, Terese; Askinis, Renatas; Kurtinaitis, 
Juozas 
Institute Oncology, Vilnius University, Vilnius, Lithuania
Background: Evaluate efﬁcacy of combined surgical and conservative 
treatments women lung cancer in Lithuania. 
Matherial and Methods: From 1996-2003 y.y. 316 patients (women) 
entered study evaluating results of lung cancer treatment in Institute of 
Oncology, Vilnius University. Patients were stratiﬁed according: age, 
stage of disease, smoking status, morfology and treatment (surgery 
alone or with other treatment v/s no surgery involved). According age 
patients distribution were: 35-49 y. - 43 pts (13,6%), 50-64 y. - 124 
pts (39,2%), 65-74 y. - 108 pts (34,1%) and 75+ y. - 41 pts (12,9%). 
Morfology: adenocarcinoma - 173 pts (54,7%), epidermoid - 43 pts 
(13,6%), SCLC - 31 pts (9,8%), carcinoid - 9 pts (2,8%), cancer cells 
- 19 pts (6,0%) and nonclassiﬁed carcinoma - 41 pts (12,9%); By stage: 
I stage - 55 pts (18,4%), II stage - 66 pts (20,8%), III stage - 100 pts 
(31,6%), IV stage - 95 (30,1%); By smoking status: non smokers - 241 
pts (76,2% ), smokers - 75 pts (23,7% ). Surgery was performed in 85 
pts (26,9%), combined surgical treatment - 61 pts (19,3%), combined 
conservative treatment - 103 pts (32,6%), 67 pts (21, 2%) received 
palliation. 
Results: overall 5 years survival 23% of cases. 5 years survival by age: 
<50 y. - 18%, 50-64 y. - 20%, 65-74 y. - 19%, +75 y. - 17% cases. 5 
years survival by stage: I stage - 52%, II stage - 25%, III stage - 10%, 
IV stage - 12%. 5 years survival by morfology: adenoCa - 22%, epider-
moid - 22%, SCLC - 10%, carcinoid - 52%, cancer cells - 22%, non-
classiﬁed carcinoma - 24%. 5 years survival by smoking status: SCLC: 
smokers 5 %, non smokers - 15%; nonclassiﬁed carcinoma: smokers 
- 0%, non smokers - 26%. 5 years survival estimate by treatment: 5 
years survival: surgery±combined treatment 25% of cases, no surgery 
involved - 10% of cases. 
Conclusions: 1. Surgical or surgical combined treatment was superior 
to conservative treatment (5 years survival 25% v/s 10%). 2. Bet-
ter treatment results were achieved in carcinoid treatment (5 y. surv. 
- 52%), NSCLC - 22%, SCLC - 10% and nonclassiﬁed carcinomas 
- 24%. 3. Overall 5 y. survival in women lung cancer in this study was 
achieved in 23% of cases. 
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Induction chemotherapy versus induction chemoradiotherapy for 
pathological N2 non-small cell lung cancer
Date, Hiroshi1 Kiura, Katsuyuki1 Takigawa, Nagio1 Tabata, Masahiro1 
Fujiwara, Yoshiro1 Toyooka, Shinichi1 Aoe, Motoi1 Katayama, Hideki2 
Ueoka, Hiroshi2 
1 Okayama University, Okayama, Japan 2 Sanyo National Hospital, 
Ube, Japan 
Background: Several studies have suggested that induction therapy 
followed by surgical resection may improve the outcome in patients 
with stage IIIa (N2) non-small-cell lung cancer (NSCLC), however, 
optimal induction strategy has not been deﬁned. 
Methods: We retrospectively reviewed the medical records of 33 
patients with stage IIIa NSCLC having mediastinal lymph node metas-
tases proved by mediastinoscopy. Fifteen patients received induction 
chemotherapy (CT) between 1995 and 1999. Eighteen patients received 
induction chemoradiotherapy (CRT) between 2000 and 2006. For 
induction CT, CDDP (60 mg m-2) and CPT-11 (50 mg m-2) were given 
on days 1, 8, 29, and 36. For induction CRT, cisplatin (40 mg/m2) and 
docetaxel (40 mg/m2) were given on days 1, 8, 29, and 36 along with 
concurrent thoracic irradiation at a dose of 46 Gy (2 Gy/fraction/day). 
Induction was followed by surgical resection in 4-6 weeks.
Results: Preoperative patients’ characteristics were similar between 
CT and CRT (Table 1). All 33 patients underwent surgical resection 
after the induction therapy. The rate of pathological effectiveness of 
the main tumor (the rate of Ef2 or Ef3) was signiﬁcantly higher in 
CRT than in CT (72.2% vs 26.7%, p = 0.022). Treatment related death 
was encountered in one CT patient but in none of CRT patients. The 
5-year survival rate was signiﬁcantly better in CRT (68.2%) than in CT 
(26.7%) as shown in Figure 1.
Conclusions: Induction CRT may provide signiﬁcantly better patho-
logical effectiveness than induction CT, thus may improve the survival 
for patients with stage IIIa (N2) NSCLC. 
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ERCC1 and Beta Tubulin III (BTUB) isoform expression by 
Immunofluorescence (IF) may correlate with survival after 
combined modality therapy (CMT) for stage III NSCLC
Edelman, Martin J.1 Kwong, King1 Suntharalingam, Mohan1 Tan, 
Ming1 Lesko, Steve2 Ts’o, Paul2 
1 University of Maryland Greenebaum Cancer Center, Baltimore, MD, 
USA 2 CCC Diagnostics, LLC, Baltimore, MD, USA 
Background: Multimodality therapy has clearly improved outcome 
in Stage III NSCLC. However, the majority of patients still succumb 
to disease. Platinum based therapy, utilized both concurrently with 
radiotherapy as well as induction/consolidation therapy is central to 
this approach. Recent data in adjuvant therapy and in stage IV disease 
indicate that ERCC1 expression correlates with platinum responsive-
ness. BTUB isoform expression has been correlated to sensitivity to an-
titubulin agents. We utilized a novel, quantiﬁable, IF method to assess 
ERCC1 and beta tubulin III expression in pre-treatment specimens and 
correlated with overall survival from a prospective institutional study.
Methods: Pts with path III A/B disease, PS 0-1 were eligible. CMT 
consisted of induction therapy with escalating doses of Carboplatin 
(C)(AUC=1), and Vinorelbine (V) 5-15mg/m2 q wk, with concurrent 
69.6 Gy (1.2 Gy bid/5 d/wk for 29 d). Pts with negative mediasti-
nal nodes after chemoXRT underwent resection, if feasible. All pts 
received additional chemoRx consisting of C/V at AUC=5 d1, 25mg/m2 
d1,8 q 21 d X 3 followed by docetaxel 75mg/m2 2 q 21 d x 3. Parafﬁn 
embedded tumor specimens were analyzed by IF staining for ERCC1 
and BTUB. Anti-ERCC-1 was directly labeled with Alexa 594 while 
anti-beta-tubulin was counterstained with Alexa 532 dye. IF was 
measured quantitatively with a computerized microscopy system and 
expressed as the mean of the average ﬂuorescence per pixel. IF expres-
sion in the tumor sections is measured in 1000 tumor cells utilizing 5 
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digital images of various areas of the tumor. Determinations of poten-
tial sensitivity or resistance was based on the relative level of compara-
tive IF expression and comparison with an in vitro ﬂuorescent reference 
standard. The criteria for resistance versus susceptible is established 
from the internal comparison for the in vitro studies. Within the eight 
lung cancer cell lines in culture, the comparatively resistant cells 
require 7-10 fold higher drug concentrations for the same cytotoxicity 
(IC50) than the comparatively susceptible cells. The expression levels 
of ERCC-1 and beta-tubulin III correlates well with these requirements 
of drug concentrations for same cytotoxicity (IC50 ) with a Pearson 
coefﬁcient of about 0.9. IF signals exceeding those of the most resistant 
and overexpressing line were considered resistant. Final characteriza-
tion of the tumor was based upon both the ERCC1 and BTUB staining. 
Specimens sensitive to both agents were characterized as sensitive (S), 
all others were considered resistant (R). Laboratory personnel were 
blinded to pt identity and outcomes.
Results: 47 pts were enrolled on the study between 1/2000 and 5/2004. 
All pts have completed therapy. The median overall survival is 29.6 
months and median event free survival is 16.9 months. Specimens 
from 10 pts have been analyzed. 4 were sensitive and 6 resistant. There 
was no difference in event free survival between the S and R groups. 
However, there was a trend (p=.08) towards improved overall survival 
in the S group.
Conclusions: 1. This IF assessement can be rapidly performed on 
parafﬁn blocks and provides a quantitative assessment of ERCC1 and 
BTUBB III expression that is not observer dependent. 2. These very 
preliminary data indicate that ERCC1 and BTUBB III may correlate 
with survival in Stage III NSCLC treated with CMT. Additional data 
will be available by the time of the meeting. 
Supported by a Maryland Industrial Partnerships grant.
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Phase 1/2 trial of ABT-751 in combination with pemetrexed vs 
pemetrexed alone in subjects with advanced or metastatic non-
small-cell lung cancer (NSCLC)
Eliopoulos, Helen1 Oliveira, Moacyr2 Mauer, Ann3 Rudin, Charles4 
Coates, Andrew1 Zhou, Xiangdong1 Xiong, Hao1 Hagey, Anne1 
1 Abbott, Abbott Park, IL, USA 2 NorthWest Medical Specialties, PLLC, 
Tacoma, WA, USA 3 University of Chicago, Chicago, IL, USA 4 Sidney 
Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, 
MD, USA 
Background: ABT-751 is an orally bioavailable sulfonamide that binds 
to the colchicine site on β-tubulin and inhibits polymerization of micro-
tubules. Pemetrexed (Alimta®) is an antineoplastic agent that interrupts 
cell replication. Both compounds have been evaluated individually in 
advanced NSCLC subjects and in combination in preclinical xenograft 
models.
Methods: The Phase 1 open-label dose escalation portion of the 
study was designed to determine the maximum tolerated dose (MTD) 
and recommended Phase 2 dose (RPTD) of ABT-751 when adminis-
tered with pemetrexed. For each cycle, subjects received 500 mg/m2 
pemetrexed IV on Day 1 and ABT-751 orally QD for 14 consecutive 
days followed by 7 days off drug. Dose levels of ABT-751 began at 
200 mg and escalated in 50 mg increments. Pharmacokinetic sampling 
was performed on Day 1 of Cycle 1. The Phase 2 portion of the study 
was designed to determine the effect of ABT-751 plus pemetrexed on 
progression-free survival.
Results: Nine subjects have been accrued into the Phase 1 portion of 
the study. The MTD and RPTD were determined to be 200 mg of ABT-
751 QD for 14 days. Two of 6 subjects (33%) in the 250 mg cohort 
experienced a dose-limiting toxicity (DLT) (1 grade 3 [CTCAE version 
3.0] neuropathy; 1 grade 5 intestinal infarction, shown by CT scan to be 
consistent with ischemic infarction). Two additional subjects reported 
grade 3 treatment-emergent adverse events (fatigue [2], constipation 
[1], dyspnea [1]), which the investigator considered probably or pos-
sibly related to ABT-751. Preliminary pharmacokinetic results for ABT-
751 after the concomitant administration of ABT-751 and pemetrexed 
were comparable to those after the administration of ABT-751 alone 
in a previous Phase 1 study. Preliminary laboratory data for grade 3/4 
hematologic parameters indicate the incidence of neutropenia was 2/8 
(25%) and thrombocytopenia and anemia were each 0% for subjects 
receiving ABT-751 and pemetrexed. The incidences from the peme-
trexed label are 5% for neutropenia, 2% for thrombocytopenia, and 
8% for anemia. Two subjects had partial responses; 1 conﬁrmed and 1 
unconﬁrmed.
Pharmacokinetic parameters of ABT-751 after single oral dose of ABT-751
 
200 mg ABT-751 
With Pemetrexed
200 mg ABT-751 
Alone#
250 mg ABT-751 
With Pemetrexed##
250 mg ABT-751 
Alone#
N 3 23 5 3
Tmax (h) 0.8 ± 0.3 2.0 ± 1.3 3.2 ± 1.8 1.3 ± 0.6
Cmax (μg/mL) 9.9 ± 9.8 9.1 ± 4.5 8.2 ± 4.2 10.9 ± 3.3
AUC0-8 
(μg*h/mL) 27.2 ± 12.9 33.0 ± 10.1 34.9 ± 15.8 45.5 ± 10.5
#From a previous Phase 1 study M01-303
## One subject had unusually low drug plasma levels, which resulted iin lower means for Cmax and AUC0-8 
for the 250 mg dose.
Conclusions: Both the MTD and RPTD of the combination of ABT-
751 and pemetrexed have been determined. Coadministration of peme-
trexed with ABT-751 does not appear to affect the pharmacokinetic 
proﬁle of ABT-751.
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Randomized phase III Trial comparing three chemotherapy 
regimens in advanced non-small cell lung cancer (NSCLC)
Gaafar, Rabab M. 
Medical Oncology, Cairo, Egypt
Background: Lung cancer is the leading cause of cancer related death 
worldwide in both males and females. Despite the poor prognosis of 
patients with advanced NCSLC, treatment with the new generation che-
motherapy agents has improved survival, quality of life and decreased 
toxicity compared to older regimens.
Methods: In this study, patients were randomly assigned to receive 
either paclitaxel 175mg/m2 (day1) or gemcitabine 1,250mg/m2 (days 
1 and 8) both combined with cisplatin 80mg/m2 (day 1) or paclitaxel 
175mg/m2 (day1) combined with gemcitabine 1,250 mg/m2 (days 1 
and 8) as ﬁrst line therapy for stage III b having pleural effusion or 
supraclavicular lymph node metastasis and stage IV NSCLC. Primary 
endpoint was comparison of overall survival for the 3 arms. Secondary 
endpoints included response rate, progression free survival and toxici-
ties.
Results: Sixty two patients (arm A, 19, arm B 23, arm C 20 patients) 
were enrolled. Major clinical characteristics in arm A/B/C were: 
Median age 51, 50, and 47 years, stage IV 14 %, 13 %, and 16 %, 
